Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 11/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17817245 | 1.00 | DNM1 (0.45) | DNM1HTTENPP2SLC22A1LSS | |
| SCHEMBL332175 | 0.92 | DNM1 (0.43) | DNM1HTTENPP2SLC22A1LSS | |
| SCHEMBL330533 | 0.92 | DNM1 (0.43) | DNM1HTTENPP2SLC22A1LSS | |
| SCHEMBL14556985 | 0.92 | ENPP2 (0.45) | DNM1HTTENPP2SLC22A1LSS | |
| SCHEMBL331764 | 0.92 | DNM1 (0.43) | DNM1HTTENPP2SLC22A1LSS | |
| SCHEMBL330853 | 0.92 | DNM1 (0.43) | DNM1HTTENPP2SLC22A1LSS | |
| Water SCHEMBL29991942 | 0.90 | ENPP2 (0.44) | DNM1HTTENPP2SLC22A1LSS | |
| SCHEMBL330578 | 0.90 | DNM1 (0.48) | DNM1HTTSLC22A1LSSKMT2A | |
| SCHEMBL332291 | 0.90 | DNM1 (0.48) | DNM1HTTSLC22A1LSSKMT2A | |
| SCHEMBL330697 | 0.90 | DNM1 (0.48) | DNM1HTTSLC22A1LSSKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | DNM1 3773/4885HTT 4263/4885ENPP2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.